Christopher G Kanakry
Overview
Explore the profile of Christopher G Kanakry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
2184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mehta R, Choe H, Saultz J, Gong Z, Sharma P, Al-Juhaishi T, et al.
Am J Hematol
. 2025 Mar;
PMID: 40071498
Cytomegalovirus (CMV) infection post-hematopoietic cell transplantation (HCT) remains a significant cause of morbidity and mortality. While letermovir prophylaxis is available for CMV-seropositive recipients, optimal donor selection for CMV-seronegative recipients remains...
2.
Hyder M, Dimitrova D, Sabina R, DeVries A, McCune J, McAdams M, et al.
Blood Adv
. 2025 Feb;
PMID: 39908565
High-dose post-transplantation cyclophosphamide (HD-PTCy), given at 50 mg/kg/day on days +3/+4, is a standard-of-care graft-versus-host disease (GVHD) prophylaxis for allogeneic hematopoietic cell transplantation (HCT). Our murine MHC-haploidentical HCT studies suggested...
3.
Kajdic A, Deuitch N, Bresciani E, Davis J, Craft K, Chong S, et al.
Br J Haematol
. 2025 Jan;
206(3):1000-1003.
PMID: 39865735
No abstract available.
4.
Hickey C, Zhang M, Allbee-Johnson M, Romee R, Majhail N, Al Malki M, et al.
Transplant Cell Ther
. 2025 Jan;
31(3):174.e1-174.e12.
PMID: 39755256
Background: Post-transplant cyclophosphamide (PTCy) is a commonly used graft-vs-host disease (GVHD) prophylaxis, particularly in the setting of haploidentical (haplo) hematopoietic cell transplantation (HCT). The rate of graft failure has been...
5.
Banerjee C, Conlan S, Mostaghim A, Michelin A, Arduino M, Mattioli M, et al.
Transpl Infect Dis
. 2024 Dec;
27(1):e14425.
PMID: 39731681
We report a case of Acanthamoeba infection in an HCT recipient with steroid-refractory GVHD. We highlight the multiple challenges that free-living ameba infections present to the clinician, the clinical laboratory,...
6.
Holter-Chakrabarty J, McNally L, Levine J, Ferrara J, Vesely S, Kanakry C, et al.
Radiol Imaging Cancer
. 2024 Dec;
7(1):e240096.
PMID: 39670843
Purpose To determine whether fluorine 18 (F) fluorothymidine (FLT) PET imaging alone or combined with Mount Sinai Acute GVHD International Consortium (MAGIC) biomarkers could help identify subclinical gastrointestinal graft versus...
7.
Mohanan E, Shen G, Ren S, Fan H, Moua K, Karolak A, et al.
Clin Transl Sci
. 2024 Aug;
17(8):e70014.
PMID: 39162578
Dose optimization of sirolimus may further improve outcomes in allogeneic hematopoietic cell transplant (HCT) patients receiving post-transplantation cyclophosphamide (PTCy) to prevent graft-versus-host disease (GVHD). Sirolimus exposure-response association studies in HCT...
8.
Shanmugasundaram K, Napier S, Dimitrova D, Stokes A, Wilder J, Chai A, et al.
Bone Marrow Transplant
. 2024 Aug;
59(11):1513-1524.
PMID: 39134710
The therapeutic efficacy of donor lymphocyte infusions (DLIs) given after allogeneic hematopoietic cell transplantation (HCT) is limited by risk of graft-versus-host disease (GVHD). Post-transplantation cyclophosphamide (PTCy) effectively prevents severe GVHD,...
9.
Li N, Bowling J, de Hoog S, Aneke C, Youn J, Shahegh S, et al.
mBio
. 2024 Jul;
15(8):e0014424.
PMID: 38953355
Dimorphism is known among the etiologic agents of endemic mycoses as well as in filamentous . Under appropriate thermal conditions, mononuclear yeast forms alternate with multi-nucleate hyphae. Here, we describe...
10.
Saliba R, Kanakry C, Gadalla S, Kebriaei P, Rezvani K, Champlin R, et al.
Am J Hematol
. 2023 Oct;
99(1):38-47.
PMID: 37850688
We investigated the impact of donor age (younger [≤35 years] vs. older [>35 years]) after accounting for other non-HLA and HLA factors on outcomes of patients with acute myeloid leukemia...